A series of N-benzyl-4-((heteroaryl)methyl)-benzamides as a novel class of direct InhA inhibitors by high-throughput screening were identified by Guardia et al. These compounds displayed potent activity against MTB (MIC90: 6 to 125 μM), maintaining activity versus KatG mutant clinical strains (IC50: 12–31 μM) and emerging as a potential tool against MDR-TB and XDR-TB. This evidence concerns the gene INHA and tuberculosis.